Mon08032020

Robins Global News & Noticias



COVID-19 Map Tracker | COVID-19 News Features


  • Career Exam Study
    Career Exam Study
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

RobinsPost News Network

+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Alercell Announces 280 Million Dollar Agreement for COVID-19 Rapid Blood Tests


BOZEMAN, Mont., July 30, 2020 (GLOBE NEWSWIRE) -- Alercell today announced that it has reached an agreement for distribution of COVID-19 rapid antibody serology tests with manufacturer Medigen Biotechnology Corp, (TPEX 3176 MEDIGEN) a publicly traded company-controlling shareholder of TBG Biotechnology Corp.

ALERCELL is a biotechnology company based in Montana, USA with offices in New York City.  Alercell has run internal validation studies of a number of rapid antibody tests notified to the US Food and Drug Administration under Emergency Use Authority (EUA) and has retained just three for distribution.  Alercell research supports that these tests are efficient, valid and have superior accuracy.  "We are confident that the TBG Rapid Antibody Test is among the most accurate serology tests and we are pleased to work with Medigen," said Dr Alexandre Scheer, Chief Medical Officer of Alercell. 

FDA has listed as notified almost 200 tests under EUA authority and is in the process of reviewing and terminating some notifications based on failure to validate through independent NCI review. It is therefore extremely important for medical companies to buy from a source that internally validates the tests presented, as some of the products made available on the market may be questionable and may become obsolete quickly if the FDA is not satisfied by the NCI review.

Medigen/TBG has received full EUA authorization from FDA for its PCR test and TBG is expecting EUA authorization for its rapid serology test, which can now be marketed in notified status pending full EUA review, within days/weeks.

In addition, Alercell has researched the production capacity of various manufacturers and found that some manufacturers have limited industrial capacity, whereas Alercell has the capacity to deliver tests in very large quantity. 

With this $280,000,000 distribution agreement, Alercell is positioning itself at the forefront of the fight against Covid-19 in North America.

About Alercell

Alercell is a Biotechnology company based in Bozeman, Montana. Created in 2020 by a group of veterans of medical research, Alercell's principle business is in the discovery, development, manufacture, and sale of an efficient treatment to the Covid-19 pandemic and Alercell is currently actively seeking a Covid 19 advanced treatment plan using stem cells. Alercell intends to expand its operations to a broad and diversified line of health care solutions to infectious diseases. For more information, please visit: www.alercell.com 

Media Contact 

Mr. Frederic Scheer, CEO
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Alexandre Scheer, Chief Medical Officer
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  
Tel: (406) 233-6434




Posted: 2020-07-31 02:21:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.





Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Alercell Announces 280 Million Dollar Agreement for COVID-19 Rapid Blood Tests | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Alercell Announces 280 Million Dollar Agreement for COVID-19 Rapid Blood Tests

Thu, 30 Jul 2020 22:14:00 GMT

BOZEMAN, Mont., July 30, 2020 (GLOBE NEWSWIRE) -- Alercell today announced that it has reached an agreement for distribution of COVID-19 rapid antibody serology tests with manufacturer Medigen ...

Alercell Announces 280 Million Dollar Agreement for COVID-19 Rapid Blood Tests

Thu, 30 Jul 2020 19:21:00 GMT

Alercell today announced that it has reached an agreement for distribution of COVID-19 rapid antibody serology tests ...

Atomo Diagnostics and Access Bio partner to expand access to COVID-19 blood-based rapid testing in North America

Tue, 28 Jul 2020 17:25:00 GMT

Atomo has announced that it has signed a binding agreement with US-based diagnostics specialist Access Bio Inc. (KOSDAQ: 950130) (Access Bio) that will see Atomo supply its unique, integrated rapid ...

Atomo Diagnostics and Access Bio partner to expand access to COVID-19 blood-based rapid testing in North America

Tue, 28 Jul 2020 12:22:00 GMT

SYDNEY, July 28, 2020 /PRNewswire/ -- Atomo has announced that it has signed a binding agreement ... standard IgG/IgM COVID-19 rapid test uses a separate lancet to generate a blood sample and ...

UArizona aims to provide rapid tests for those exposed to biothreats, such as COVID-19

Tue, 28 Jul 2020 06:35:00 GMT

To better protect those on the frontlines of battlefields or an event like the COVID-19 pandemic, University of Arizona College of Medicine - Phoenix scientists with the Center for Applied ...

Related News Story Videos From Youtube






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.